2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 127

Elevated Levels of the Neutrophil Extracellular Trap-binding Protein LILRA3 in Primary Antiphospholipid Syndrome

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 125

Elevated Proliferative Capacity of CD8+ T Cells in Giant Cell Arteritis

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 412

Elevated Serum BAFF Levels in Patients with Dermatomyositis: Association with Interstitial Lung Disease

Muscle Biology, Myositis & Myopathies Poster I

9:00AM-11:00AM: Abstract Number: 640

Elevated Serum Interleukin-23 Level in Patients with Systemic Lupus Erythematosus Is Associated with Disease Activity, Clinical and Immunological Markers

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 358

Emergency Department Encounters in a Large US Payer Database: Tophaceous versus Non-tophaceous Gout Patients

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 343

Emergency Department Length of Stay in Patients with Acute Gout

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 221

Emergency Department Utilization for Fibromyalgia Patients

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 57

Endothelial Progenitor Cells in the Pathophysiology of Interstitial Lung Disease Associated with Rheumatoid Arthritis

RA – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 730

Energy Levels: An Overlooked Element in Patient Assessment in Scleroderma

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 594

Enhanced Performance of the ASAS Classification Criteria by Deletion of Non-Discriminatory Clinical Items: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 154

Enhancing Medicine Trainees’ Exposure to Gout Diagnosis and Management Through an Interprofessional Approach in the Primary Care Setting

Education Poster

9:00AM-11:00AM: Abstract Number: 695

Environmental and Atmospheric Factors in Systemic Lupus Erythematosus: A Regression Analysis

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 187

Epidemiology of JIA-Associated Uveitis: Environmental Factors and Disease Characteristics of a JIA-Associated Uveitis Cohort

Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Abstract Number: 553

Etanercept Biosimilar GP 2015 (Erelzi®) in Rheumatic Diseases: Interim Analysis of Real-World Data from COMPACT: A Multicentric, Prospective, Observational Cohort Study

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 501

EULAR Definition of “Arthralgia Suspicious for Progression to Rheumatoid Arthritis” in a Cohort of Patients Included in a Program for Rapid Diagnosis: Role of Ultrasound and Antibodies

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].